普伐他汀对颈动脉粥样硬化患者血浆同型半胱氨酸水平及颈动脉粥样硬化程度的影响

摘要

Objective To investigate the effects of Pravastatin on level of plasma homocysteine (Hcy) and degree of carotid atberosclerosis (CAS) in patients with CAS. Methods One hundred patients with CAS ( the elder CAS group, age≥60 years old, 50 cases; the middle-aged CAS group,age ＜60 years old, 50 cases) were treated with Pravastatin 20 mg/d for two months. The level of plasma Hcy was detected and compared with 50 healthy controls ( normal control group). The degree of CAS was determined by carotid color doppler before and after the treatment. Results The levels of plasma Hcy in the two CAS groups were significantly higher than that in the normal control group ( all P ＜0. 01 ). The levels of plasma Hey and the degree of CAS in the two CAS groups after treatment were significantly lower than those before treatment (all P ＜ 0. 01 ). Conclusion Pravastatin can significantly decrease the level of plasma Hey in CAS patients, and can ameliorate the CAS degree.%目的:探讨普伐他汀对颈动脉粥样硬化(CAS)患者血浆同型半胱氨酸(Hey)水平及颈动脉粥样硬化程度的影响.方法:给100例CAS患者(≥ 60岁50例,老年CAS组;<60岁50例,中年CAS组)普伐他汀20mg/d,连续服用2个月;检测治疗前后血浆Hey水平并与50例健康体检者(正常对照组)比较;采用颈动脉超声多普勒仪检查治疗前后CAS程度.结果:两CAS组患者血浆Hey水平均明显高于正常对照组(均P<0.01).两CAS组患者治疗后血浆Hey水平及CAS程度均较治疗前明显降低(均P<0.01).结论:普伐他汀能明显降低CAS患者血浆Hey水平,并能减轻其CAS程度.